A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Clinical trial NCT02752035 · COMPLETED

Trial details

NCT number: NCT02752035
Sponsor: Astellas Pharma Global Development, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Start date: 2016-08-01
Primary completion: 2023-03-10
Enrollment: 183

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.